A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.
Understanding how cells turn genes on and off is one of biology's most enduring mysteries. Now, a new technology developed by chemist Brian Liau and his collaborators at Harvard offers an ...
Over the past two decades, synthetic biology has fueled advancements across a broad range of disciplines, including agriculture, bioremediation, biofuel production, and chemical manufacturing. Today, ...
After Intellia Therapeutics paused a pair of phase 3 trials for its CRISPR therapy in response to a liver safety signal, the ...
A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...
While some practices remain controversial or speculative, biohackers are united by a shared curiosity: how can we engineer ...
Seven years after the first gene-edited babies were revealed, biotech startup Manhattan Genomics is reviving the idea of ...
How AI, robotics, and precision medicine are transforming cancer care—bridging hope, technology, and humanity in the ongoing ...
As flu season approaches and public health officials roll out their annual push for vaccination, Allen Institute scientists ...
In a world first, a bespoke gene-editing therapy benefitted one child. Now reseachers plan to launch a clinical trial of the ...
Major change for rare disease treatments on way, signals MHRA: United Kingdom Tuesday, November 4, 2025, 13:00 Hrs [IST] The rulebook for rare disease therapies will be overhauled ...
In a world first, a bespoke gene-editing therapy benefited one child. Now researchers plan to launch a clinical trial of the approach ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback